Skip to search formSkip to main contentSkip to account menu

PCK3145

Known as: Prostate-Secretory Protein-94-Derived Peptide PCK3145 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC)-The US experience.
4650 Background: PCK3145 is a synthetic 15-mer peptide derived from the natural sequence of amino acids of Prostate Secretory… 
2007
2007
PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC)
A11 Background: PCK3145 is a synthetic 15-mer peptide which bears homology to Prostate Secretory Protein (PSP94). It subserves… 
2007
2007
Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein with In Vitro and In Vivo Activity Against Non-Hodgkin’s Lymphoma and Other Hematologic Malignancies.
Prostate secretory protein 94 (PSP-94) has been shown to exert anti-tumor activity against prostate cancer cells, particularly in… 
2006
2006
Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling
PCK3145 is a synthetic peptide corresponding to amino acids 31–45 of prostate secretory protein 94 which can reduce experimental… 
Review
2005
Review
2005
Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer
This review focuses on the promising roles of prostate secretory protein of 94 amino acids (PSP-94) and one of its derived… 
2005
2005
A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer
2004
2004
A Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein Can Reduce Tumor Growth, Experimental Skeletal Metastases, and Malignancy-Associated Hypercalcemia
In previous studies, we have shown that prostate secretory protein (PSP-94) can reduce prostate cancer growth in vivo. In the… 
2004
2004
A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer…
4636 Background: PCK3145 is a synthetic 15-mer peptide derived from the prostate secretory protein (PSP94) sequence. PCK3145 has… 
2004
2004
Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostatic cancer (HRPC) using serum markers.
4692 Background: Evaluation of efficacy for new treatment of HRPC is both challenging and rewarding as new targets are elucidated… 
2004
2004
Safety, tolerability, pharmacokinetic and escalating single doses of PCK3145 in patients with metastatic hormone resistant prostatic cancer (HRPC)
4473 Introduction and Objective: Prostate secretory protein (PSP94) within PSA and PAP is one of the three most abundant protein… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)